- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04406324
COVID-19: Respiratory and Sleep Follow-up (Co-SURVIVORS)
COVID-19: Prospective Follow-up of Pulmonary Function, Sleep Disorders, Quality of Life and Post-traumatic Stress
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Europe and in particular Italy, Spain and France are currently affected by the coronavirus 2019-nCoV pandemic, whose immediate prognosis is linked to the development of acute respiratory distress syndrome (ARDS). Beyond the long-term adverse effects on respiratory health and reduced exercise capacity, other complications will occur. These include a more rapid progression of cardiometabolic diseases, a secondary epidemic of disabling post-traumatic stress disorder, and severe sleep disorders. The current project aims at a multidisciplinary assessment of respiratory, cardiac, sleep and mental health sequelae, three months after SARS-CoV-2 diagnosis in order to better characterize these complications.
Three aspects will be targeted in this study : (i) long-term monitoring of deterioration in lung function, (ii) screening for sleep respiratory disorders (sleep apnea syndrome, obesity hypoventilation syndrome) and iii) characterization of sleep disorders and design of specialized intervention to improve sleep quality.
This study is a prospective, multicentric cohort study that aims at constituting a cohort of 400 patients who will be screened for pulmonary, cardiac, sleep, or psychological sequelae 3 months after their diagnosis. They will be then followed for 5 years. The primary outcome will be the diffusion capacity of carbon monoxide (DLCO) 3 months after the diagnosis. Other secondary outcomes will include:
- prevalence of sleep disorders and sleep disordered breathing 3 months after diagnosis and their evolution until 5 years;
- prevalence of cardiac, exercise capacity, respiratory and ventilatory muscles impairments at 3 months and their evolution until 5 years;
- characterization of homogeneous groups of patients who were infected with SARS-CoV-2 and have respiratory, cardiometabolic and/or sleep complications, 3 months after diagnosis (latent class analysis) and evaluate their evolution until 5 years
- determine the prevalence of radiological sequelae at 3 months, and their evolution until 5 years
- determine the psycho-social impact (quality of life, post-traumatic stress, anxiety, productivity at work) at 3 months and its evolution until 5 years
Type d'étude
Inscription (Anticipé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Renaud Tamisier, MD, PhD, MBA
- Numéro de téléphone: +33 476 768 469
- E-mail: rtamisier@chu-grenoble.fr
Lieux d'étude
-
-
-
Bobigny, France, 93000
- Recrutement
- Hôpital Avicenne
-
Contact:
- Carole Planes, MD, Pr
-
Créteil, France, 94000
- Recrutement
- Centre Hospitalier Henri Mondor, APHP
-
Contact:
- Genevieve Derumeaux, MD, Pr
-
Grenoble, France, 38043
- Recrutement
- Chu Grenoble Alpes
-
Sous-enquêteur:
- Marie DESTORS, MD
-
Contact:
- Renaud Tamisier, MD, Pr, PhD
- Numéro de téléphone: (0033)476768469
- E-mail: rtamisier@chu-grenoble.fr
-
Sous-enquêteur:
- Jean-Louis Pepin, MD, Pr, PhD
-
Sous-enquêteur:
- Sam Bayat, MD, Pr, PhD
-
Sous-enquêteur:
- Anne-Laure Mounayar, MD
-
Sous-enquêteur:
- Nicolas Terzi, MD, Pr
-
Nancy, France, 54000
- Pas encore de recrutement
- CHRU Nancy
-
Contact:
- Bruno Chenuel, MD, Pr
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Male or Female, aged > 18 years
- With a positive diagnosis for SARS-COVID-19, confirmed by RT-PCR or with compatible symptoms
- Signed informed consent by patient
- Affiliated to a French social and health insurance system or equivalent
- For biological collection: patient eligible for sampling (weight >50kg and hemoglobin >7g/dL) and signed inform consent for collection
Exclusion Criteria:
- Pregnant or breastfeeding women
- Prisoners or patients who require protection by the law
- Patients not affiliated to a French social and health insurance system or equivalent
- Ages <18 years
- Diagnosis of infection by other pathogen than SARS-COVID-19 or no indication of infection by COVID-19
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
---|---|
SARS-CoV-2 patients
Patients infected by SARS-CoV-2
|
No Intervention.
The study consists in a prospective clinical longitudinal follow-up
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Diffusion Capacity for Carbon Monoxide (CO) 3 months after COVID diagnosis
Délai: 3 months after COVID diagnosis
|
Pulmonary function 3 months after COVID diagnosis, as measured by diffusion capacity of carbon monoxide (DLCO)
|
3 months after COVID diagnosis
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Prevalence of Sleep Disordered Breathing (SDB) 3 months after COVID diagnosis
Délai: 3 months after COVID diagnosis
|
Prevalence of Sleep Disordered Breathing, as measured by polysomnography
|
3 months after COVID diagnosis
|
Prevalence of sleep disorders 3 months after COVID diagnosis
Délai: 3 months after COVID diagnosis
|
Prevalence of sleep disorders, as measured by polysomnography
|
3 months after COVID diagnosis
|
Prevalence of ventilatory muscle function impairments, 3 months after COVID diagnosis
Délai: 3 months after COVID diagnosis
|
Prevalence of ventilatory impairments measured by pulmonary function tests
|
3 months after COVID diagnosis
|
Prevalence of cardiac impairments 3 months after COVID diagnosis
Délai: 3 months after COVID diagnosis
|
Prevalence of cardiac impairments measured by cardiac echography
|
3 months after COVID diagnosis
|
Follow-up of pulmonary diffusion capacity of carbon monoxide
Délai: From Baseline (3 months after COVID diagnosis) to 5 years
|
Pulmonary function as measured by diffusion capacity of carbon monoxide (DLCO)
|
From Baseline (3 months after COVID diagnosis) to 5 years
|
Follow-up of sleep disorders treatment compliance
Délai: From Baseline (3 months after COVID diagnosis) to 5 years
|
Assessment of SDB treatments adherence will be monitored in hours/night
|
From Baseline (3 months after COVID diagnosis) to 5 years
|
Follow-up of sleep disorders treatments efficacy
Délai: From Baseline (3 months after COVID diagnosis) to 5 years
|
Assessment of SDB treatments efficacy will be based on the residual AHI index (Apnea Hypopnea/hour) under treatment
|
From Baseline (3 months after COVID diagnosis) to 5 years
|
HLA alleles aspect of COVID clinical presentation
Délai: 3 months after COVID diagnosis
|
HLA alleles will be assessed as a component of genetic immune capacity
|
3 months after COVID diagnosis
|
KIR loci aspect of COVID clinical presentation
Délai: 3 months after COVID diagnosis
|
KIR loci will be assessed as a different component of genetic immune capacity
|
3 months after COVID diagnosis
|
metabolomic aspect of COVID clinical presentation
Délai: 3 months after COVID diagnosis
|
metabolome expression in sera
|
3 months after COVID diagnosis
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Renaud Tamisier, MD, PhD, MBA, University Hospital Grenoble Aples
Publications et liens utiles
Publications générales
- Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585. Erratum In: JAMA. 2021 Mar 16;325(11):1113.
- Herridge MS, Moss M, Hough CL, Hopkins RO, Rice TW, Bienvenu OJ, Azoulay E. Recovery and outcomes after the acute respiratory distress syndrome (ARDS) in patients and their family caregivers. Intensive Care Med. 2016 May;42(5):725-738. doi: 10.1007/s00134-016-4321-8. Epub 2016 Mar 30.
- Hui DS, Joynt GM, Wong KT, Gomersall CD, Li TS, Antonio G, Ko FW, Chan MC, Chan DP, Tong MW, Rainer TH, Ahuja AT, Cockram CS, Sung JJ. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax. 2005 May;60(5):401-9. doi: 10.1136/thx.2004.030205.
- Burnham EL, Hyzy RC, Paine R 3rd, Coley C 2nd, Kelly AM, Quint LE, Lynch D, Janssen WJ, Moss M, Standiford TJ. Chest CT features are associated with poorer quality of life in acute lung injury survivors. Crit Care Med. 2013 Feb;41(2):445-56. doi: 10.1097/CCM.0b013e31826a5062.
- Luyt CE, Combes A, Becquemin MH, Beigelman-Aubry C, Hatem S, Brun AL, Zraik N, Carrat F, Grenier PA, Richard JM, Mercat A, Brochard L, Brun-Buisson C, Chastre J; REVA Study Group. Long-term outcomes of pandemic 2009 influenza A(H1N1)-associated severe ARDS. Chest. 2012 Sep;142(3):583-592. doi: 10.1378/chest.11-2196.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 38RC20.157
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur COVID-19 [feminine]
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkPas encore de recrutementSyndrome post-COVID-19 | Longue COVID | Longue Covid19 | État post-COVID-19 | Syndrome post-COVID | Condition post-COVID-19, non précisée | État post-COVIDPays-Bas
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlComplétéSéquelles post-aiguës de la COVID-19 | État post-COVID-19 | Long-COVID | Syndrome chronique du COVID-19Italie
-
Indonesia UniversityRecrutementSyndrome post-COVID-19 | Longue COVID | État post-COVID-19 | Syndrome post-COVID | Longue COVID-19Indonésie
-
Yang I. PachankisActif, ne recrute pasInfection respiratoire COVID-19 | Syndrome de stress COVID-19 | Effet indésirable du vaccin COVID-19 | Thromboembolie associée au COVID-19 | Syndrome de soins post-intensifs COVID-19 | AVC associé à la COVID-19Chine
-
Massachusetts General HospitalRecrutementSyndrome post-aigu COVID-19 | Longue COVID | Séquelles post-aiguës de la COVID-19 | Longue COVID-19États-Unis
-
Sheba Medical CenterInconnue
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecrutementCOVID-19 Pneumonie | Infection respiratoire COVID-19 | Pandémie de covid-19 | COVID-19 Syndrome de Détresse Respiratoire Aiguë | COVID-19-Pneumonie associée | Coagulopathie associée au COVID 19 | COVID-19 (maladie à coronavirus 2019) | Thromboembolie associée au COVID-19Grèce
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecrutementPandémie de covid-19 | Vaccins contre le covid-19 | Maladie à virus COVID-19Indonésie
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital; Yulin No.2 Hospital et autres collaborateursRecrutementCOVID-19 [feminine] | Syndrome post-COVID-19 | COVID-19 post-aiguë | COVID-19 aiguëChine
-
Jonathann Kuo, MDActif, ne recrute pasInfection par le SRAS-CoV2 | Syndrome post-COVID-19 | Dysautonomie | Syndrome post-aigu COVID-19 | Longue COVID | Longue Covid19 | COVID-19 récurrent | COVID-19 post-aiguë | Infection COVID-19 post-aiguë | Séquelles post-aiguës de la COVID-19 | Dysautonomie comme trouble | Dysautonomie Syndrome d'hypotension... et d'autres conditionsÉtats-Unis
Essais cliniques sur No intervention
-
Otsuka Pharmaceutical Factory, Inc.CelerionComplété
-
University of MinnesotaComplété
-
Assistance Publique - Hôpitaux de ParisComplété
-
Milton S. Hershey Medical CenterPas encore de recrutementMaladies du foie | NASH - Stéatohépatite non alcoolique | NASH
-
University of CologneComplétéAccident vasculaire cérébral | ApraxieAllemagne
-
Northwestern UniversityComplétéLa dépression | AnxiétéÉtats-Unis
-
H2O Health and Agriculture LLCInconnuePneumonie | DiarrhéeGuatemala
-
Eunah Cho, MDComplétéRécupération postopératoireCorée, République de
-
University of California, Los AngelesInconnue
-
Johns Hopkins UniversityAstraZenecaInscription sur invitationCancer du poumon non à petites cellules (NSCLC)États-Unis